

Supplementary Table S1: Best overall response by RECIST 1.1 and PCWG2 for bone

	MBC (N = 22)				mCRPC (N = 12)	
	1.25 mg/kg Q2W n = 6	1 mg/kg WK1245 n = 5	100 mg Q2W n = 5	100 mg QW n = 6	1.25 mg/kg Q2W n = 8	1 mg/kg WK1245 n = 4
Data are n (%)						
Best response by RECIST						
Complete response	0	0	0	0	0	0
Partial response	0	0	0	0	0	0
Stable disease	3 (50)	0	1 (20)	1 (17)	3 (38)	0
Progressive disease	2 (33)	5 (100)	4 (80)	5 (83)	1 (13)	3 (75)
Not evaluable ^a	1 (17)	0	0	0	4 (50)	1 (25)
Overall response rate (CR/PR)	0	0	0	0	0	0
Disease control rate (CR/PR/SD)	3 (50)	0	1 (20)	1 (17)	3 (38)	0
Best response by PCWG2						
Stable disease	-	-	-	-	2 (25)	2 (50)
Progressive disease	-	-	-	-	4 (50)	1 (25)
Not evaluable	-	-	-	-	2 (25)	1 (25)

Data cutoff date: 10 May 2018.

A response (CR or PR) required confirmation ≥ 4 weeks after initial response.

Assignment of SD required 7 weeks (49 days) elapsed between first dose and disease assessment.

^aPatients without a valid response assessment ≥ 7 weeks after enrollment that had not already progressed were assigned a best response of Not Evaluable.

Abbreviations: CR, complete response; MBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; PCWG2, Prostate Cancer Clinical Trials Working Group; PD, progressive disease; PR, partial response; SD, stable disease; QW, every week; Q2W, every two weeks; WK1245, weeks 1, 2, 4, and 5.